Ryan Michael Reyes

8PUBLICATIONS
14CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Nov 19, 2025
Anti-PD-L2 immunotherapy is efficacious against melanoma in aged hosts through IL-17 and IFNγ signalling.

Carlos O Ontiveros, Myrna G Garcia, Clare E Murray

|Mar 06, 2023
Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice.

Myrna G Garcia, Yilun Deng, Clare Murray

|Feb 09, 2023
Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects.

Haiyan Bai, Alvaro S Padron, Yilun Deng

|Oct 05, 2021
γδ T Cells Support Antigen-Specific αβ T cell-Mediated Antitumor Responses during BCG Treatment for Bladder Cancer.

Niannian Ji, Neelam Mukherjee, Zhen-Ju Shu

|Apr 14, 2021
CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.

Ryan Michael Reyes, Yilun Deng, Deyi Zhang

|Mar 03, 2021
Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study.

Niannian Ji, Neelam Mukherjee, Ryan M Reyes

Pageof 2

Frequent Collaborators

8 joint publications

Tyler J Curiel

2 joint publications

Harshita Gupta

2 joint publications

Aravind Kancharla

2 joint publications

Robert S Svatek